These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
120 related articles for article (PubMed ID: 4462865)
1. In-vivo testing of polymers for thrombogenicity. Daniels AU; Mortensen JD Biomater Med Devices Artif Organs; 1974; 2(4):365-77. PubMed ID: 4462865 [No Abstract] [Full Text] [Related]
2. [Thromboresistance of polymeric materials in construction of an artificial heart and devices for assisted circulation]. Chepurov AK; Kozlov VK Med Tekh; 1977; (2):22-6. PubMed ID: 881966 [No Abstract] [Full Text] [Related]
3. Microporous flow surface variation and short term thrombogenicity in dogs. White RA; Shors E; Miranda RM; Klein SR; Goldberg L; Bosco P; Nelson RJ Biomaterials; 1982 Jul; 3(3):145-9. PubMed ID: 7115857 [No Abstract] [Full Text] [Related]
4. Non-thrombogenicity of organic polymers by blending with alkylamine-heparin complexes. Kashiwagi T; Ito Y; Imanishi Y Biomaterials; 1993 Dec; 14(15):1145-53. PubMed ID: 8130319 [TBL] [Abstract][Full Text] [Related]
5. Platelet adhesion to heparin-bonded and heparin-free surfaces. Rembaum A; Yen SP; Ingram M; Newton JF; Hu CL Biomater Med Devices Artif Organs; 1973; 1(1):99-119. PubMed ID: 4766641 [No Abstract] [Full Text] [Related]
6. Study of surface charge of the intima and artificial materials in relation to thrombogenicity. Thubrikar M; Reich T; Cadoff I J Biomech; 1980; 13(8):663-6. PubMed ID: 6252208 [No Abstract] [Full Text] [Related]
7. [Theory of antithrombogenic surfaces. I]. Hildebrandt J; Schaps P Z Exp Chir; 1973; 6(6):355-61. PubMed ID: 4601541 [No Abstract] [Full Text] [Related]
8. Three years' experience in vivo and in vitro with surfaces and devices treated by the heparin complex method. Leininger RI; Crowley JP; Falb RD; Grode GA Trans Am Soc Artif Intern Organs; 1972; 18(0):312-5. PubMed ID: 4610965 [No Abstract] [Full Text] [Related]
9. Effect of surface porosity on early thrombogenicity using vascular grafts with two surfaces in sequence. Goldberg L; Bosco P; Shors E; Klein S; Nelson R; White R Trans Am Soc Artif Intern Organs; 1981; 27():517-21. PubMed ID: 7331121 [TBL] [Abstract][Full Text] [Related]
10. Blood compatibility of surfaces modified by plasma polymerization. Yeh YS; Iriyama Y; Matsuzawa Y; Hanson SR; Yasuda H J Biomed Mater Res; 1988 Sep; 22(9):795-818. PubMed ID: 3220845 [TBL] [Abstract][Full Text] [Related]
11. Mechanism of antithrombogenicity of a new heparinized hydrophilic polymer: chronic in vivo studies and clinical application. Idezuki Y; Watanabe H; Hagiwara M; Kanasugi K; Mori Y Trans Am Soc Artif Intern Organs; 1975; 21():436-49. PubMed ID: 1146018 [TBL] [Abstract][Full Text] [Related]
12. Biomaterials in medical devices. Bruck SD Trans Am Soc Artif Intern Organs; 1972; 18(0):1-9. PubMed ID: 4610962 [No Abstract] [Full Text] [Related]
13. Factors influencing platelet consumption by polyacrylamide hydrogels. Hanson SR; Harker LA; Ratner BD; Hoffman AS Ann Biomed Eng; 1979; 7(3-4):357-67. PubMed ID: 121213 [No Abstract] [Full Text] [Related]
14. Reduced thrombogenicity of polymers having phospholipid polar groups. Ishihara K; Aragaki R; Ueda T; Watenabe A; Nakabayashi N J Biomed Mater Res; 1990 Aug; 24(8):1069-77. PubMed ID: 2394763 [TBL] [Abstract][Full Text] [Related]
15. The current status of in vivo screening of synthetic implant materials for blood compatibility. Gott VL; Furuse A Med Instrum; 1973; 7(2):121-4. PubMed ID: 4718485 [No Abstract] [Full Text] [Related]
16. Thrombogenicity of a new injectable biocompatible elastomer for aneurysm exclusion, compared to expanded polytetrafluoroethylene in a human ex vivo model. van der Steenhoven TJ; Bosman WM; Tersteeg C; Jacobs MJ; Moll FL; de Groot PG; Heyligers JM Eur J Vasc Endovasc Surg; 2012 Jun; 43(6):675-80. PubMed ID: 22436262 [TBL] [Abstract][Full Text] [Related]